Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations

Affiliations

¹ Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
² Department of Medical Oncology, Second Tumor Hospital of Heilongjiang Province, Harbin 150088, China.

Editorial

Minghui Zhang et al. J Thorac Dis. 2016 Oct.

. 2016 Oct;8(10):E1293-E1295.

doi: 10.21037/jtd.2016.10.87.

¹ Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
² Department of Medical Oncology, Second Tumor Hospital of Heilongjiang Province, Harbin 150088, China.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Cheng Y, et al. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9. J Clin Oncol. 2016. PMID: 27507876 Clinical Trial.

1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271-89. 10.3322/caac.21349 - DOI - PubMed
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. 10.3322/caac.21338 - DOI - PubMed
1. Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw 2016;14:255-64. - PMC - PubMed
1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
1. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. 10.1016/S1470-2045(09)70364-X - DOI - PubMed